

DAFTAR PUSTAKA

- Ackland, P., 2013. Prevalence, Detection, Evaluation and Management of Chronic Kidney Disease. *In: D. Goldsmith, S. Jayawardene & P. Ackland, eds. **ABC of Kidney Disease***. West Sussex: John Wiley & Sons, pp. 15-22.
- Barrett, K. E., Barman, S. M., Scott, B. & Brooks, H. L., 2012. Renal Physiology. *In: **Ganong's Review of Medical Physiology***. New York: McGraw Hill, pp. 674-680.
- Boldt, J., 2010. Use of Albumin : an Update. **British Journal of Anaesthesia**.
- Callaghan, C., Shine, & Lasserson, D.S., 2011. **Chronic Kidney Disease**: a large scale population-based study of the effects of introducing the CKD for eGFR reporting, p. 4.
- Campbell, K., Bogard, J., & Millichamp, A., 2014. **Nutrition Prescription to Achieve Positive Outcome in Chronic Kidney Disease**: A Systemic Review, pp. 417-419.
- Cipolle, R.J., Strand, L.M., and Moley, P.C., 2004. **Pharmaceutical Care Practice: The Clinicians Guide**, New York: McGraw-Hill Companies, Inc. pp.382-384
- Cohen, S. D. & Kimmel, P. L., 2007. Nutritional Status, Psychological Issues and Survival in Hemodialysis Patients. **Contrib Nephrol**, Volume 155, pp. 1-17.
- Curhan, G.C., 2015. Nephrolithiasis. *In: D.L. Longo, D.L. Kasper, J.L. Jameson, A.S. Fauci, S.L. Hauser, and J. Loscalzo (Eds.). **Harrison's Principles of Internal Medicines***, Ed. 19th, New York: McGraw-Hill Companies, pp. 1866-1870.

- Depkes RI, 1995. **Farmakope Indonesia Edisi 4**. Jakarta: Departemen Kesehatan. pp. 69-70.
- Franch-Arcas, G., 2001. The Meaning of Hypoalbuminemia in Clinical Practice. **Clinical Nutrition**, 20(3), pp. 265-269.
- Gatta, A., Verardo, A. & Bolognesi, M., 2012. Hypoalbuminemia. **Intern Emerg Med**, 7(3), pp. 193-199.
- Greene R.J., Harris N.O., Goodyer L.I., 2000, **Pathology and Therapeutic for Pharmacist, A Basic for Clinical Pharmacy Practice**, 2nd Edition, London : Pharmaceutical Press, p. 150-153, 176-179, 183-184.
- Guyton, A.C and Hall, J.E., 2006. Glomerular Filtration, Renal Blood Flow, and Their Control. *In* : Guyton, A.C and Hall, J.E. **Textbook of Medical Physiology**, Ed. 11th, Philadelphia : Elsevier Saunders Inc., p. 307-311.
- Hahn, G. R., 2011. Colloid Fluids. *In*: G. R. Hahn, ed. **Critical Fluid Therapy in The Perioperative Setting**. New York: Cambridge University Press, pp. 11-16.
- Hall, J. E., 2010. **Guyton and Hall: Textbook of Medical Physiology**. 12th ed. New York: Saunders, pp. 413-416.
- Hasan, I. & Indra, T. A., 2008. Peran Albumin dalam Penatalaksanaan Sirosis Hati. **Medicinus**, 21(2), p. 3.
- Herrmann, F. R., Safran, C., Levkoff, S. E. & Minaker, K. L., 1992. Serum Albumin Level on Admission as a Predictor of Death, Length of Stay, and Readmission. **Arch Intern Med**, 152(1), pp. 125-130.
- Hudson, J. Q. & Wazny, L. D., 2014. Chronic Kidney Disease. *In*: J. T. Dipiro, ed. **Pharmacotherapy and Patophysiology**

- Approach 9th Edition.** New York: McGraw Hill, pp. 633-670.
- Join Formulary Committee, 2014. **British National Formulary.** 67 ed. London: Pharmaceutical Press., pp. 859-861.
- Joy, M.S., 2005. Chronic Kidney Disease: Progression Modifying Therapies. *In* : DiPiro J.T.,(Eds), **Pharmacotherapy A Pathophysiologic Approach**, 6th Edition, New York : The McGraw-Hill Companies, Inc, p. 799-820.
- Kepmenkes RI, 2014. **Riset Kesehatan Dasar**, Jakarta: Kemenkes RI.
- Kementrian Kesehatan RI, 2011. **Pedoman Intepretasi Data Klinik.** Jakarta: Kemenkes, pp. 3-7, 27-43.
- Kidney Disease Outcome Quality Initiative Guidelines. 2007. **Definition and Classification of Stages of Chronic Kidney Disease**, Part 4, Guideline 1, New york : National Kidney Foundation Inc., pp. 547-551, 568-569.
- Konsensus Pengendalian dan Pencegahan Diabetes Mellitus tipe 2 di Indonesia, 2011. **Diabetes dengan Nefropati Diabetik**, Jakarta. pp. 56-57.
- Krauss, A.G and Hak, L.J., 2000. Chronic Renal Disease. *In* : Herfindal, E.T and Gourley, D.R. **Textbook of Therapeutic Drug and Disease Management**, Ed. 7th, Vol. 1, Philadelphia : Lippincott Williams & Wilkins, p. 449-453, 463-472.
- Mason, D.L., Assimon, M.M., 2013. Chronic Kidney Disease. *In*: Alldredge, B.K., Corelli, R.L., Ernst, M.E., Guglielmo, B.J., Jacobson, P.A., Kradjan, W.A., Williams, B.R.

- (Eds.). *Applied Therapeutics: The Clinical Use of Drugs*. Ed, 10th, Philadelphia: Lippincott Williams&Wilkins, pp. 764-780.
- McEvoy, G. M. et al., 2011. **AHFS Drug Information Essentials**. Bethesda: American Society of Health-System Pharmacists.
- McPhee, S. J. and Ganong, W. F., 2006. Renal Disease. *Pathophysiology of Disease An Introduction to Clinical Medicines*, Ed. 5th, New York: McGraw-Hill Companies, pp. 462-481.
- National Kidney Foundation, 2005. K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. **Chronic Kidney Disease**, 45(4), pp. S1-S154.
- Nitsch, D., 2013. Assosiations of estimated glomerular filtration rate and albuminuria with mortality and renal failure, pp. 3-4.
- Nolin, T.D., Himmelfarb, J., and Matzke, G.R., 2002. Drug Induced Kidney Disease. *In* : DiPiro, J.T., Wells, B.G., and Posey, L.M. **Pharmacotherapy A Pathophysiology Approach**, Ed. 6th, New York : Mc Graw Hill Medical Publishing Division, p.910.
- Pagana, K. D. & Pagana, T. J., 2011. **Mosby's Diagnostic and Laboratory Test Reference**. 11th ed. St. Louis: Elsevier., pp.352-354.
- Perlman, R. L., Heung, M. & Ix, J. H., 2014. Renal Disease. Dalam: G. D. Hammer & S. J. McPhee, penyunt. **Pathophysiology of Disease: An Introduction to**

- Clinical Medicine 7th Edition.** New York: McGraw-Hill, pp. 455-481.
- Peters, T., 1995. **All About Albumin - Biochemistry, Genetics, and Medical Applications.** New York: Academic Press., pp. 12-13.
- Rennke, H. G. & Denker, B. M., 2014. **Renal Pathophysiology: The Essentials.** 4th ed. Philadelphia: Lippincott Williams & Wilkins., pp. 591-594.
- Seifter, J.L., 2015. Urinary Tract Obstruction. *In*: D.L. Longo, D.L. Kasper, J.L. Jameson, A.S. Fauci, S.L. Hauser, and J. Loscalzo (Eds.). **Harrison's Principles of Internal Medicines**, Ed. 19th, New York: McGraw-Hill Companies, pp. 1871-1876.
- Shargel L, Pong SW, Yu ABC, 2005. **Applied Biopharmaceutics & Pharmacokinetics**, 5th Edition, New York : The McGraw-Hill Companies, Inc, p. 134,673.
- Soni, N., 2009. Human Albumin Solutions and the Controversy of Crystalloids Versus Coloid. *In*: M. Contreras, ed. **ABC of Tranfusions.** West Sussex: Wiley Blackwell, pp. 48-53.
- Sulistiyoningrum, E., 2014. Perubahan Seluler dan Molekuler Pada Nefropati Diabetik. **Mandala of Health**, Vol. 7 No. 1, hal. 514-520.
- Wilson, Lorraine M., 2006. Gangguan Sistem Ginjal. *In* : Hartanto, H., Susi, N., Wulansari, P., dan Mahanani, D.A. **Patofisiologi : Konsep Klinis Proses-Proses Penyakit**, Ed. 6, Vol. 2, Jakarta : EGC, Hal. 865; 917-918; 951-952; 964-965.

- Wing, M. R., Raj, D. S. & Velasquez, M. T., 2015. Protein Energy Metabolism in Chronic Kidney Disease. Dalam: P. L. Kimmel & M. E. Rosenberg, penyunt. **Chronic Renal Disease**. Amsterdam: Academic Press, pp. 106-125.
- Yamagata, K., Ishida, K., Sairenchi, T., Takahashi, H., Ohba, S., Shiigai, T., Narita, M., Koyama, A., 2007. Risk Factors for Chronic Kidney Disease in a Community-based Population: a 10-year follow-up study. *Kidney International*, Vol. 71, pp.159-166.

